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Abstract Because the occurrence of infective endo-
carditis (IE) continues to be associated with high mor-
tality, a working group was created by the Dutch So-
ciety of Cardiology to examine how the most recent
European Society of Cardiology (ESC) guidelines for
IE management could be implemented most effec-
tively in the Netherlands. In order to investigate cur-
rent Dutch IE practices, the working group conducted
a country-wide survey. Based on the results obtained,
it was concluded that most ESC recommendations
could be endorsed, albeit with some adjustments. For
instance, the suggested pre-operative screening and
treatment of nasal carriers of Staphylococcus aureus
as formulated in the ESC guideline was found to be
dissimilar to current Dutch practice, and was there-
fore made less restrictive. The recently adapted ESC
diagnostic criteria for IE were endorsed, while the
practical employment of the relevant diagnostic tech-
niques was simplified in an adapted flowchart. In ad-
dition, the presence of a multidisciplinary, so-called
‘endocarditis team’ in tertiary centres was proposed as
a quality indicator. An adapted flowchart specifically
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tailored to Dutch practice for microbiological diag-
nostic purposes was constructed. Lastly, the working
group recommended the Stichting Werkgroep Antibi-
oticabeleid (SWAB; Dutch Working Party on Antibiotic
Policy) guidelines for IE treatment instead of the an-
tibiotic regimens proposed by the ESC.
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Background and introduction
One of the oldest cardiac diseases, infective endo-
carditis (IE), remains one of the most fatal mani-
festations of heart disease [1]. Despite considerable
progress in diagnosis and treatment, the in-hospital
mortality of IE continues to be about 20%, essentially
unchanged during the past decades [2].
The importance of IE is reflected in the frequent
publication of new guidelines, for instance by the
E. H. Natour
Department of Thoracic Surgery, Maastricht University
Medical Centre, Maastricht, The Netherlands
J. ten Oever
Department of Internal Medicine and Radboud Centre for
Infectious diseases, Radboud University Medical Centre,
Nijmegen, The Netherlands
A. L. J. Kortlever-van der Spek · B. H. Stegeman
Knowledge Institute of the Federation of Medical Specialists,
Utrecht, The Netherlands
N. J. Verkaik
Department of Medical Microbiology and Infectious
Diseases, Erasmus Medical Centre, Rotterdam, The
Netherlands
Implementation of the 2015 European Society of Cardiology guidelines
Review Article
Table 1 Selection of recommendations by the working group with regard to the European Society of Cardiology (ESC)
guidelines. SWAB Stichting Werkgroep Antibioticabeleid (Dutch Working Party on Antibiotic Policy)
Topic Recommendations in ESC guidelines Recommendation by the working group
Antibiotic prophylaxis Reserve antibiotic prophylaxis for high-risk individu-
als undergoing dental procedures
No change or comment by the working group
Prevention of infection before
cardiac or vascular interven-
tions
Screen every patient and treat Staphylococcus aureus
carriers only pre-operatively
Pre-operative screening and/or treatment of nasal carriage of
Staphylococcus aureus is recommended before elective surgery
in order to treat carriersa
Microbiological diagnosis Use the recommendation as presented in the ESC
guidelines
Use flowchart as presented in Fig. 1 a
Diagnostic imaging and criteria Use diagnostic ESC criteria and the recommendation
presented in the guidelines
Use diagnostic ESC criteria and the flowchart as presented in
Fig. 2 a
Endocarditis team Centres without cardio-thoracic facilities must con-
sult the regional endocarditis team in cases of (sus-
pected) IE
No change or comment by the working group
Antimicrobial therapy Antimicrobial therapy according to the ESC guidelines Antimicrobial therapy according to SWAB guidelinesa
Surgery Indication and timing of surgery as presented in the
guidelines
No change or comment for the indication of surgery
Timing of surgery determined by the specialists involveda
Discharge Transthoracic echo after completion of therapy
Regular follow-up including blood samples
Good oral health maintenance
No change or comment by the working group
aDifferent recommendation made by the working group compared with the ESC guidelines
European Society of Cardiology (ESC) [1]. In 2017,
the Dutch Society of Cardiology created a working
group—funded by the Quality Foundation of the
Dutch Medical Specialists (SKMS)—to investigate
whether and how the recommendations summarised
in the most recent ESC guidelines on IE could be
implemented most effectively in the Netherlands. To
investigate current Dutch IE practices, the working
group conducted a short country-wide survey. The
medical topics raised in the survey are presented
in Tab. 1. This report summarises the findings and
recommendations of the working group.
Prevention and prophylaxis
Although widespread antibiotic prophylaxis for IE has
long been considered effective, the policy for liberal
use of antibiotic prophylaxis has gradually changed to
more restricted indications. Of note, the 2008 guide-
lines of the National Institute of Health and Clinical
Excellence (NICE) from the UK recommended that an-
tibiotic prophylaxis should be abandoned completely
[3]. However, this recommendation was revised af-
ter a patient with aortic valve prosthesis died from
IE after undergoing a dental procedure without—in
line with the NICE guidelines—the use of prophylaxis.
The NICE guidelines from 2016 recommend dentists
to inform the patient about the level of risk and let
him or her decide whether or not to receive antibi-
otic prophylaxis [4]. The strategy currently endorsed
by the American College of Cardiology (ACC), Ameri-
can Heart Association (AHA) and ESC reserves antibi-
otic prophylaxis for individuals with cardiac disease at
high risk of IE, e.g. for patients with a prosthetic valve,
a history of IE, or with cyanotic congenital heart dis-
ease undergoing a dental procedure with a high risk of
bacteraemia (usually involving perforation of the gin-
giva) [1, 5]. Of course, proper oral hygiene is strongly
promoted universally. The working group decided to
endorse the recommendations of the ESC guidelines
on prophylaxis in high-risk subjects without changes
or comments [1].
Nasal carriers of Staphylococcus aureus have more
infections after cardiac surgery [6], and the pre-oper-
ative eradication of this micro-organism is thus im-
portant. To this end, two options are available. In
the first, all subjects—without additional testing—are
treated locally with an antibiotic ointment, usually
mupirocin. Another option is to screen every patient,
and to treat S. aureus carriers only. The ESC guide-
lines recommend only the latter procedure. But the
merits of the two methods are of course compara-
ble, and this is—according to the survey—reflected
by the concomitant use of both approaches for de-
colonisation of S. aureus in Dutch hospitals. There-
fore, the text of the recommendation in Tab. 7 of the
guidelines was (slightly) adapted as follows: ‘Preop-
erative screening and/or treatment of nasal carriage
of Staphylococcus aureus is recommended before elec-
tive cardiac surgery in order to treat carriers’, while
the last recommendation of the same table (‘Systemic
local treatment without screening of Staphylococcus
aureus’ is not recommended) was deleted.
Microbiological diagnosis
Positive blood cultures remain the cornerstone of IE
diagnosis. At least three sets with sufficient volume
should be taken at 30-min intervals, and sampling
preferably be obtained from a peripheral vein. When
a micro-organism has been identified and appropriate
antimicrobial treatment is commenced based on sus-
ceptibility results, blood cultures should be repeated
every 48–72h until blood cultures remain sterile to
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verify the effectiveness of the therapeutic regimen.
Blood-culture-negative IE refers to IE in which no
causative micro-organism can be identified using
standard culture methods. In such instances, bacteria
such as Bartonella spp. or Coxiella burnetii, fungi or
fastidious bacteria may be in play and additional di-
agnostic testing may be required. Table 12 and Fig. 2
in the ESC guidelines refer to these circumstances.
However, some microbiological tests included therein
are not available in the Netherlands. The working
group has therefore developed a flowchart adapted to
Dutch practice (Fig. 1).
Fig. 1 Flowchart of micro-
biological tests for infective
endocarditis in The Nether-
lands. IE Infective endo-
carditis, BC blood cultures,
SWAB Stichting Werkgroep
Antibiotica Beleid (Dutch
Working Party on Antibiotic
Policy), PCR polymerase
chain reaction. aIf the di-
agnostic test is not avail-
able, send the blood sam-
ples and/or blood cultures
to a reference laboratory.
bSo as not to miss Cutibac-
terium acnes and/or if blood
cultures were drawn while
receiving antimicrobial ther-
apy. cBartonella spp. (IgM,
IgG), Coxiella burnetii (in-
cluding indirect immunoflu-
orescent assay phase I IgG),
Legionella spp. (IgM, IgG),
Mycoplasma spp. (IgM,
IgG). dSpecific PCRs: Bar-
tonella spp., Coxiella bur-
netii, Legionella spp., My-
coplasma spp., Tropheryma
whipplei
Clinical suspicion of IE
BC (3 sets with 30-min interval)
Antibiotics (SWAB guidelines 2019)
No further diagnostic 
tests for IE
Do the followingᵃ:    
Switch to therapy for BC-negative 
IE
BC incubation up to 14 daysᵇ
Do serology ͨ
On indication: Brucella spp. 
serology and/or mycobacterial 
blood cultures. 
Specific PCRs ͩ  on blood (and 
consider 16S PCR)
16S PCR, Specific PCRs ͩ  and 
18S PCR on surgical material
Histological test (marantic 
endocarditis?)
Inoculate the BC bottles after 
incubation on agar plates
No further diagnostic tests for IE
Consult endocarditis team if necessary 
Treat according to 
susceptibility and SWAB 
guidelines 2019
Positive
Negative  (≥3 
days) and high 
suspicion 
Negative
BC 
results
Negative and low 
suspicion 
Micro-
organism?  Positive
Micro-
organism?   
Diagnostic imaging and criteria
While the modified Duke criteria, which rely heavily
on positive blood cultures and findings compatible
with IE at echocardiography [7], remain the mainstay
for diagnosing IE, current guidelines reflect the in-
creasing importance of more advanced imaging tech-
niques [1]. In particular, computed tomography (CT),
positron emission tomography with CT (PET-CT)
and magnetic resonance imaging have emerged as
valuable additional imaging techniques that provide
complementary diagnostic information to echocar-
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diography [1]. Available data—also from the Nether-
lands—indicate increased diagnostic accuracy when
these techniques are added to the modified Duke
criteria, especially in prosthetic valve endocarditis
(PVE) [8–10]. The guidelines provide detailed recom-
mendations on the use of various imaging techniques
in both native valve IE and PVE, as well in the di-
agnosis of cardiac-device-related endocarditis [7, 8].
The working group has combined the text and fig-
ures that describe these recommendations in the ESC
guidelines into a single scheme (Fig. 2).
The diagnostic accuracy of the modified Duke cri-
teria—which merge the presence of an infective syn-
drome and endocardial involvement, classically em-
ploying echocardiography—is only moderate, in par-
Fig. 2 Flowchart of di-
agnostic imaging for in-
fective endocarditis in the
Netherlands. IE infective
endocarditis, TTE transtho-
racic echocardiogram, TEE
transoesophageal echocar-
diogram,BC blood cultures,
18F-FDG PET/CT 18F-flu-
orodeoxyglucose positron
emission tomography com-
puted tomography,
SPECT single photon emis-
sion computed tomogra-
phy, CTA computed tomog-
raphy angiography, ICE in-
tracardiac echocardiogram,
SWAB Stichting Werkgroep
Antibiotica Beleid (Dutch
Working Party on Antibi-
otic Policy). a[1, 25]. b[26].
cConsider referring to a ter-
tiary referral centre when
there is definite IE and one
or more of the following:
congenital heart disease in
pregnancy, prosthetic valve
endocarditis, heart failure,
perivalvular extension or
uncontrolled infection, em-
bolic events or cerebrovas-
cular accident, arrhythmia
or conduction disturbances
Clinical suspicion of IE
One or more of the 
following steps:
Repeat TTE/TEE/BC
18F-FDG PET/CT or 
radiolabelled leucocyte
SPECT/CT
Cardiac CTA
Imaging for embolic 
events
One or more of the 
following steps:
Repeat TTE/TEE/BC
Cardiac CTA
Imaging for embolic 
events
One or more of the 
following steps:
Repeat TTE/TEE/BC
Consider 18F-FDG PET/
CT and/or ICEᵇ  
Refer to the 
Endocarditis Team
No further 
diagnostics
Antimicrobial therapy (SWAB guidelines 2019)
Indication for surgical intervention? Discuss with 
endocarditis team
Modified Duke Criteriaᵃ  
(including TTE/TEE)
Possible  
IE?
Definite 
IE
Ongoing 
suspicion 
of IE
Native 
valve
Valve 
type/
device?
Rejected 
IE
No further 
diagnostics
Definite 
IE?
No
Yes ͨ
Uncertain
Prosthetic 
valve
Device
ticular in IE of a prosthetic valve [1, 11, 12]. Advanced
imaging techniques—as described above—may not
only be helpful in the detection of endocardial le-
sions when added to echocardiography, but also in
establishing the presence of (clinically silent) vascular
phenomena such as embolic events and infectious
aneurysm [13]. Acknowledging this, the most recent
ESC guidelines have added the identification of par-
avalvular lesions by CT and, in the setting of PVE,
abnormal activity near the site of the prosthesis on
18F-fluorodeoxyglucose (18F-FDG) PET/CT or radiola-
belled leucocyte single photon emission computed
tomography (SPECT)/CT, as a ‘major’ criterion for IE.
The currently applicable two major and five minor
criteria for IE are described in Tab. 2. Examples of pos-
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Table 2 Diagnostic criteria for infective endocarditis (IE)
according to the 2015 European Society of Cardiology
(ESC) guidelines for IE
Major criteria
1. Blood cultures positive for IE
a. Typical micro-organisms consistent with IE from 2 separate blood cul-
tures:
– Viridans streptococci, Streptococcus gallolyticus (Streptococcus bovis),
HACEK groupa, Staphylococcus aureus; or
– Community-acquired enterococci, in the absence of a primary focus; or
b. Micro-organisms consistent with IE from persistently positive blood
cultures:
–≥2 positive blood cultures of blood samples drawn >12h apart; or
– All of 3 or a majority of ≥4 separate cultures of blood (with first and last
samples drawn ≥1h apart); or
c. Coxiella burnetii phase I IgG antibody titre >1:1024
2. Imaging positive for IE
a. Echocardiogram positive for IE:
– Vegetation
– Abscess, pseudoaneurysm, intracardiac fistula
– Valvular perforation or aneurysm
– New partial dehiscence of prosthetic valve
b. Abnormal activity around the site of prosthetic valve implantation
detected by 18F-FDG PET/CT (only if the prosthesis was implanted for
>3 months)
c. Paravalvular lesions and/or vegetation detected by cardiac CTA
Minor criteria
1. Predisposing heart condition or injection drug use
2. Fever defined as temperature >38°C
3. Vascular phenomena (including those detected by imaging only)
4. Immunological phenomena (e.g. Janeway lesions, Osler’s nodes)
5. Positive blood culture but does not meet a major criterion as noted above
or serological evidence of active infection with organism consistent with IE
Definite IE
– Clinical criteria: 2 major or 1 major +3 minor or 5 minor criteria
– Pathological criteria: microorganism cultures from the vegetation or con-
firmed by histological examination of vegetation/intra-cardiac abscess
showing active endocarditis
Possible IE
– Clinical criteria: 1 major +1 minor or 3 minor criteria
Data partially derived from the 2015 ESC guidelines for IE [1]
IE infective endocarditis, 18F-FDG 18F-fluorodeoxyglucose, PET/CT positron
emission tomography/computed tomography, CTA computed tomography
angiography
aHaemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella
itive echocardiogram, 18F-FDG PET/CT and cardiac
CT are demonstrated in Fig. 3.
The ‘endocarditis team’
An important addition in the latest ESC guidelines is
the recommendation to establish a multidisciplinary
‘endocarditis team’. Such a team, comprising—at
least—a cardiologist, cardio-thoracic surgeon, infec-
tious diseases specialist, microbiologist and radiolo-
gist/nuclear medicine physician should provide the
expertise needed to treat complex IE patients. The
guidelines refer—among other things—to the team
approach adopted in France, with standardised med-
ical therapy and uniform recommendations for surgi-
cal interventions that were found to improve outcome
relative to earlier experience [14–18]. A comparable
recommendation has been made in the AHA/ACC
guidelines for the management of patients with valvu-
lar disease [19]. In line with the ESC guidelines, the
working group recommended that each of the current
16 Dutch tertiary referral centres with cardio-tho-
racic facilities create a specific regional endocarditis
team. Moreover, the working group proposed to qual-
ify the presence and composition of such a team as
a quality indicator. The working group endorsed the
ESC guidelines recommendation that centres without
cardio-thoracic facilities must consult the regional
endocarditis team in cases of (suspected) IE.
Antimicrobial therapy
There are major differences between European coun-
tries in the use of antimicrobial therapy and con-
sequently in the antibiotic resistance patterns of
pathogens. The Netherlands has the lowest rate of
antibiotic use in Europe. The result is a stable level
of antimicrobial resistance, whereas most countries
experience increasing levels each year. European
guidelines for antimicrobial therapy therefore can-
not be simply adhered to but have to be tailored to
individual countries. Recommendations for antibi-
otic therapy in the Netherlands are provided by the
Stichting Werkgroep Antibiotica Beleid (SWAB; Dutch
Working Party on Antibiotic Policy). Importantly,
SWAB recently updated their guidelines for antibiotic
treatment for IE, on the basis of an in-depth compari-
son of the most recent ESC and the AHA IE guidelines.
In cases of discordance between the recommenda-
tions in these documents, SWAB guidance is based
on a formal literature review on best current Dutch
practice, taking into consideration national resistance
patterns and dosing habits. For all these reasons,
the working group recommended the employment
of the SWAB guidelines for subsequent use in the
Netherlands [20].
Main complications and their management
Heart failure resulting from valvular regurgitation
or obstruction, uncontrolled infection and embolic
events occurring under adequate antibiotic treatment
constitute major complications of IE and may require
surgical treatment [1, 21–24]. The working group en-
dorsed the ESC indications for cardiac surgery with-
out modifications. However, the timing of the surgical
procedure was left to the discretion of the specialists
involved. In accordance with the recommendations
of the ESC guidelines, complex IE patients should be
referred early to a regional centre with cardio-thoracic
facilities. Such cases include, but are not limited to,
IE patients with congenital heart disease, PVE, preg-
nant women, patients with heart failure, uncontrolled
infection, rhythm abnormalities or stroke.
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Fig. 3 Different examples
of major imaging diagnos-
tic criteria: two cases of
positive transoesophageal
echocardiogram (a, b), one
case of positive 18F-FDG
PET/CT (c, d) and one case
of positive cardiac CT (e,
f). a A case of a mechan-
ical aortic valve with signs
of vegetation (red arrow).
The red arrow in b also
indicates a vegetation on
the aortic valve biopros-
thesis, whereas the white
arrow indicates a possible
abscess of the aortic root.
In c (fused PET/CT images)
and in d (non-attenuated
PET images) the white ar-
rows indicate 18F-FDG up-
take around the aortic valve
bioprosthesis as a sign of
possible infection. The red
arrow in e indicates a vege-
tation on one of the leaflets
of an aortic valve biopros-
thesis. Finally, the red ar-
row in f indicates a my-
cotic aneurysm alongside
the aortic valve bioprosthe-
sis
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